Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Intro. to drug metabolism enzymes
- Hydrophobicity and lipophilicity
- Log D(7.4)
- Membrane transfer
- Membrane transfer - examples
- Oral drugs and lipophilic properties
- Renal clearance
- Lipophilicity and renal clearance
- Metabolic and renal clearance
- Lipophilicity and non-renal clearance
- Phase 1 and 2 metabolism
- Metabolism of SM-10888
- Metab. and lipophilicity/clearance
- Enzymes of phase 1 and 2 metab.
- Top drugs and clearance route
- Cytochrome P450 (CYP450)
- Reactions performed by CYP450
- Enzyme to superfamily (1)
- Enzyme to superfamily (2)
- SSAR of major human CYP450s
- Top drugs and CYP450 isoforms
- Consequences of multiple CYP450
- Effect of CYP2D6 genotypes
- Terfenadine and its selectivity (1)
- Terfenadine and its selectivity (2)
- Terfenadine and its selectivity (3)
- Acidic drugs in metabolism
- Species differences in toxicity
- Other oxidative metab. proc. (1)
- Other oxidative metab. proc. (2)
- Other oxidative metab. proc. (3)
- Enzymes of phase 1 and 2 metab.
- Top drugs and clearance route
- Glucuronyl transferases
- Glucuronidation reactions
- Conjug. by glucuronyl transferases
- Other transferases
- Oral drug - pharmacok. properties
- Medicinal chemistry
- Top drugs and clearance route
Topics Covered
- Metabolism of lipophilic molecules
- Phase I and Phase II enzymes
- Location
- Mechanism
- Typical substrates
- Genetic variation
- Species variation
- Inhibition and drug interactions
- Drug design
Links
Series:
Categories:
Talk Citation
Smith, D. (2016, April 20). Introduction to drug metabolism enzymes [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/OTPG4039.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Dennis Smith has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
This talk is an introduction
to the enzymes of drug metabolism.
It will be illustrated by using
examples from pharmaceuticals.
These examples are equally
applicable to other xenobiotics.
0:18
A basic concept we need
to understand with enzymes
is the principle of
hydrophobicity and lipophilicity.
Hydrophobicity is the association
of non-polar groups or molecules
in an aqueous environment.
It arises from the tendency of water
to exclude non-polar molecules.
Lipophilicity is the affinity a molecule
for a lipophilic environment.
We measure this in a biphasic
system by determining the partition
coefficient between an aqueous
buffer and a lipophilic phase,
such as octanol.
1:03
This schematic shows
how lipophilicity
is actually quantitated.
The term we actually end
up with is log D 7.4.
The 7.4 defines the pH.
D refers to distribution
coefficient.
And because the range is
wide, we log the term,
we will also see that this fits
nicely with biological properties.
The schematic shows that
only the unionized drug
can penetrate into the lipid phase.
Drug which is present
in the aqueous phase
is a mixture of ionized
and unionized drug.
PKA determines proportion of
unionized drug versus ionized drug.
The actual intrinsic
lipophilicity, or P,
determines the partitioning
of the unionized drug between
the aqueous phase and the lipid.